Contact Us
Drug Search Results
More Filters [+]

MK-0493

Alternative Names: mk-0493, mk0493, mk 0493
Latest Update: 2022-03-01
Latest Update Note: News Article

Product Description

MK-0493 is a novel, potent, and selective agonist of the melanocortin receptor 4 (MC4R), one of the best-validated genetic targets and considered one of the most promising for the development of antiobesity therapeutics.Ê (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19741604/)

Mechanisms of Action: MCR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for MK-0493

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Obesity

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT00482196

P2

Completed

Obesity

2006-03-01

NCT00482638

P2

Completed

Obesity

2004-10-29

Recent News Events

Date

Type

Title

03/01/2022

News Article

 Terray Therapeutics Expands Leadership Team with Fez Ujjainwalla, PhD as Head of Business and Adam D. Hughes, PhD as Head of Chemistry

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions